270 related articles for article (PubMed ID: 31574517)
1. Patients with Sacral Neuromodulation: What Are the Factors Affecting Their Therapy Satisfaction?
Banakhar M; Hassouna M
Urol Int; 2019; 103(4):450-453. PubMed ID: 31574517
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
3. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
4. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
Hoda MR; Fornara P
Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
[TBL] [Abstract][Full Text] [Related]
5. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
[TBL] [Abstract][Full Text] [Related]
6. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
8. The role of neuromodulation in patients with neurogenic overactive bladder.
Lay AH; Das AK
Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
[TBL] [Abstract][Full Text] [Related]
9. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
10. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
Fletcher N
Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
[TBL] [Abstract][Full Text] [Related]
11. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
[TBL] [Abstract][Full Text] [Related]
13. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
14. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
Marinkovic SP; Ford JC
BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
[TBL] [Abstract][Full Text] [Related]
15. Sensing in Sacral Neuromodulation: A Feasibility Study in Subjects With Urinary Incontinence and Retention.
Goudelocke C; Jungbauer Nikolas LM; Bittner KC; Offutt SJ; Miller AE; Slopsema JP
Neuromodulation; 2024 Feb; 27(2):392-398. PubMed ID: 37589643
[TBL] [Abstract][Full Text] [Related]
16. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
18. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Benson K; McCrery R; Taylor C; Padron O; Blok B; de Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman H; Lane F
Neurourol Urodyn; 2020 Jun; 39(5):1482-1488. PubMed ID: 32339339
[TBL] [Abstract][Full Text] [Related]
19. Sacral neuromodulation for lower urinary tract dysfunction.
Van Kerrebroeck PE; Marcelissen TA
World J Urol; 2012 Aug; 30(4):445-50. PubMed ID: 21989816
[TBL] [Abstract][Full Text] [Related]
20. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
